Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Pfizer's expenditure on research and development from 2006 to 2018
(in million U.S. dollars)
Pfizer's expenditure on research and development 2006-2018
Pfizer is a multinational pharmaceutical company that is headquartered in New York City, New York. Pfizer’s expenditures on research and development (R&D) have been variable in recent history. A of 2018, Pfizer expended just over 8 billion U.S. dollars on R&D efforts. This is an increase from the previous year, but a decrease from 2010 when the company spent about 9.5 billion dollars on R&D.

Pfizer’s company profile

Pfizer is one of the world’s largest pharmaceutical companies. The company has pharmaceuticals in a number of therapeutic areas including oncology, endocrinology, cardiology, and neurology. The Prevnar family of drugs is Pfizer’s top revenue-generating drug group. Prevnar is a vaccine used to prevent pneumococcal pneumonia. The company has undergone several mergers and acquisitions in recent history. In 1999 Pfizer and Warner-Lambert joined, forming one of the most valuable pharmaceutical mergers of all time.

Pharmaceutical research and development

Pharmaceutical R&D is crucial for finding and creating new drug compounds and agents that have the potential to save lives (or improve medical symptoms). Pharmaceutical R&D in the U.S. has become a booming industry and spending is increasing year-over-year. The number of federally registered clinical trials in the U.S. has been increasing significantly in recent years as well. One area of health that has been significantly impacted by R&D investment is oncology. There have never been more cancer drugs in development in the United States than as of 2018.
Pfizer's expenditure on research and development from 2006 to 2018
(in million U.S. dollars)
Expenditure in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

February 2019

Region

Worldwide

Survey time period

2006 to 2018

Supplementary notes

This statistic was assembled from several editions of Pfizer's annual financial report.

Open this statistic in...
Pfizer's expenditure on research and development 2006-2018
Pfizer is a multinational pharmaceutical company that is headquartered in New York City, New York. Pfizer’s expenditures on research and development (R&D) have been variable in recent history. A of 2018, Pfizer expended just over 8 billion U.S. dollars on R&D efforts. This is an increase from the previous year, but a decrease from 2010 when the company spent about 9.5 billion dollars on R&D.

Pfizer’s company profile

Pfizer is one of the world’s largest pharmaceutical companies. The company has pharmaceuticals in a number of therapeutic areas including oncology, endocrinology, cardiology, and neurology. The Prevnar family of drugs is Pfizer’s top revenue-generating drug group. Prevnar is a vaccine used to prevent pneumococcal pneumonia. The company has undergone several mergers and acquisitions in recent history. In 1999 Pfizer and Warner-Lambert joined, forming one of the most valuable pharmaceutical mergers of all time.

Pharmaceutical research and development

Pharmaceutical R&D is crucial for finding and creating new drug compounds and agents that have the potential to save lives (or improve medical symptoms). Pharmaceutical R&D in the U.S. has become a booming industry and spending is increasing year-over-year. The number of federally registered clinical trials in the U.S. has been increasing significantly in recent years as well. One area of health that has been significantly impacted by R&D investment is oncology. There have never been more cancer drugs in development in the United States than as of 2018.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Pfizer"
  • Global positioning
  • Revenues
  • Selected top products
  • Expenditures/payments
The most important statistics
  • Other key data
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.